Protocol Ledger

NCT04293393 · Phase II · ACTIVE NOT RECRUITING

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Interventional Phase II clinical trial protocol NCT04293393 sponsored by Spanish Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-02 Enrollment: 200 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04293393
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04293393
Protocol FieldVerified Registry Value
NCT IdentifierNCT04293393
Consolidated Lead SponsorSpanish Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment200 participants (ACTUAL)
Registered Start Date2020-10-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04293393
Hospital Research SiteLocationSite Profile
Hospital Universitario Marqués de ValdecillaSantander, SpainOpen Hospital Dossier ->
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI